A Phase II, Single-Arm, Open-label Study of Itacitinib, for the prevention of cytokine Release Syndrome (CRS) induced by Immune Effector Cell Therapy

Protocol No
INCYTE-INCB-39110-211-CRS
Principal Investigator
Nirav Shah
Phase
II
Summary
Look at how effective Itacitinib is as a preventative treatment for Cytokine Release Syndrome (CRS) for people who plan to receive either Kymriah or Yescarta Immune Effector Cell (IEC) therapy.
Description
A study of Itacitinib for the Prevention of CRS induced by Immune Effector Cell Therapy
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: